Revacept(血小板黏附抑制剂)用于症状性颈动脉狭窄:多中心随机II期试验
这项国际多中心、三臂、随机、双盲、安慰剂对照的II期试验纳入症状性颈内动脉狭窄患者,在指南推荐抗血小板治疗基础上单次20分钟输注安慰剂、40 mg或120 mg Revacept。主要探索性终点为治疗后弥散加权MRI新发缺血病灶数,三组间无统计学差异;120 mg组复合安全性与有效性终点较安慰剂降低(HR 0.46,95%CI 0.21-0.99,P=0.047),40 mg组无显著差异。
要点
- 症状性颈内动脉狭窄患者在标准抗血小板治疗基础上加用Revacept 120 mg,复合安全性与有效性终点较安慰剂降低(HR 0.46,95%CI 0.21-0.99,P=0.047)。
- Revacept 40 mg组复合终点与安慰剂无显著差异(HR 0.72,95%CI 0.37-1.42,P=0.343)。
- 三组弥散加权MRI新发缺血病灶数无统计学差异(安慰剂1.16/例、40 mg组1.05/例、120 mg组0.63/例)。
核心结论
- Revacept 120 mg降低了症状性颈内动脉狭窄患者的复合安全性与有效性终点。
研究设计与样本
- 国际多中心(16个中心)、三臂、1:1:1随机、双盲、安慰剂对照、平行组研究,纳入症状性颈内动脉狭窄患者。
- 160例随机患者中158例接受研究药物(安慰剂51例、Revacept 40 mg 54例、Revacept 120 mg 53例),年龄68±10.1岁,女性24%,随访11.2±2.3个月。
- 干预为在指南推荐抗血小板治疗基础上单次20分钟输注安慰剂、Revacept 40 mg或Revacept 120 mg。
主要发现
- 每例患者新发弥散加权MRI缺血病灶数:安慰剂组1.16(95%CI 0.88-1.53)、Revacept 40 mg组1.05(95%CI 0.78-1.42;P=0.629)、Revacept 120 mg组0.63(95%CI 0.43-0.93),无统计学差异证据。
- 研究期间复合安全性与有效性终点:Revacept 120 mg组较安慰剂组降低(HR 0.46,95%CI 0.21-0.99;P=0.047)。
- 研究期间复合安全性与有效性终点:Revacept 40 mg组与安慰剂组无显著差异(HR 0.72,95%CI 0.37-1.42;P=0.343)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with symptomatic internal carotid artery (ICA) stenosis are at high risk of recurrent ischemic stroke and require early interventional treatment and antiplatelet therapy. Increased bleeding rates might counterbalance the periprocedural efficacy of intensified platelet inhibition. We aim to investigate, whether Revacept, a competitive antagonist of glycoprotein VI, adjunct to standard antiplatelet therapy reduces the occurrence of ischemic lesions in patients with symptomatic ICA stenosis. METHODS: International, multicenter (16 sites), 3-arm, randomized (1:1:1), double-blind, and placebo-controlled study with parallel groups, including patients with symptomatic ICA stenosis. A single infusion over 20 minutes of either placebo, 40 mg or 120 mg Revacept in addition to guideline-conform antiplatelet therapy was evaluated with regard to the exploratory efficacy end point: Number of new ischemic lesions on diffusion-weighted magnetic resonance imaging after treatment initiation. Main clinical outcome was the combined safety and efficacy end point including any stroke or death, transient ischemic attack, myocardial infarction, coronary intervention, and bleeding complications during follow-up. RESULTS: Out of 160 randomized patients, 158 patients (68±10.1 years, 24% female) received study medication (51 patients placebo, 54 patients 40 mg Revacept and 53 patients 120 mg Revacept) and were followed for 11.2±2.3 months. A total of 1.16 (95% CI, 0.88-1.53)/1.05 (95% CI, 0.78-1.42; P=0.629)/0.63 (95% CI, 0.43-0.93) new diffusion-weighted magnetic resonance imaging lesions per patient were detected in the placebo/40 mg/120 mg Revacept groups, without statistical evidence of a difference. A reduction of the combined safety and efficacy end point during the study period was observed in patients who received 120 mg (HR, 0.46 [95% CI, 0.21-0.99]; P=0.047), but not 40 mg Revacept compared with placebo (HR, 0.72 [95% CI, 0.37-1.42]; P=0.343). CONCLUSIONS: Revacept 120 mg reduced the combined safety and efficacy end point in patients with symptomatic ICA stenosis. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique Identifier: NCT01645306.
引用
- Uphaus T, Richards T, Weimar C, et al. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial. Stroke. 2022. PMID: 35695006. doi:10.1161/STROKEAHA.121.037006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。